Invion Limited (IVX:ASX)


right-arrow Created with Sketch. 0.002 (15.38%)
MCAP $83.09M
Last trade 16.10pm 30/07/2021 20mins delayed

Latest Announcements

22/07/2021 Price SensitivePSIVXInvion Limited
09/07/2021IVXInvion Limited
18/06/2021IVXInvion Limited
11/06/2021IVXInvion Limited
11/06/2021IVXInvion Limited
11/06/2021IVXInvion Limited
11/06/2021IVXInvion Limited
09/06/2021IVXInvion Limited

Company Overview

Invion Limited is a clinical-stage life sciences (drug development) company. The Company is engaged in the completion of clinical development programs and targeted business development programs associated with its approximately three drug assets, such as INV102 (nadolol), INV103 (ala-Cpn10) and INV104 (zafirlukast). It focuses on the development of treatments for opportunities in chronic inflammatory and respiratory disease. INV102 (nadolol) is a beta adrenergic biased ligand targeted to treat chronic inflammatory airway diseases via the reversal of mucous metaplasia in the airway epithelium. INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein, which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesized to maintain and restore immune homeostasis.

IVX in the news

Search Previous Announcements